Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients: JEMS

Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients: JEMS - JEMS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34210

Enrollment

190

Registered

2010-11-08

Start date

2011-01-31

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disorder of the central nervous system Multiple Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All candidates for this study must have the ability to understand the purpose of the study and provide signed and dated informed consent. All patients with a diagnosis of MS of any type, irrespective of their treatment, are eligible to participate once.

Exclusion criteria

Exclusion criteria: All candidates not able to understand the purpose of the study and not able to provide signed and dated informed consent.

Design outcomes

Primary

Measure	Time frame
Prevalence of anti-JCV antibodies will be estimated as the number of patients with anti-JCV antibodies detected in serum divided by the total number of patients with a serum sample that was evaluated. Prevalence of anti-JCV antibodies will also be estimated by the criteria described in the objective of the study.	—

Countries

Netherlands

Outcome results